- About Us
- Our Programs
- Our Events
- uCity Square
- Support Us
June 7, 2017
PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular announces the expansion of its proprietary Membrane Proteome Array™ to now consist of 5,300 unique human membrane proteins, representing nearly the entire human membrane proteome, making it the broadest platform of its kind for antibody specificity profiling and de-orphaning.
Off-target drug binding accounts for half of all safety failures during clinical drug development. To address this concern, the Membrane Proteome Array provides the unprecedented ability for highly sensitive and comprehensive screening of biotherapeutic candidates against nearly all human membrane proteins, which are the targets for most drugs. Screening for off-target interactions early in therapeutic development de-risks lead selection and can minimize adverse clinical effects.
“The Membrane Proteome Array represents a convergence of Integral Molecular’s 15 years of experience as a leader in membrane protein expression, and its high-throughput expression analysis capabilities,” says Benjamin Doranz, President and CEO of Integral Molecular. “We are excited by the potential of this technology to improve drug safety and find new drug targets.”
In addition to drug safety testing, the expanded Membrane Proteome Array is being used to de-orphan antibodies that show therapeutic promise but do not yet have an assigned target or mechanism-of-action. The Membrane Proteome Array is also actively being used to identify novel receptors for viruses and immuno-oncology targets.
About Integral Molecular
Integral Molecular is a research-driven biotechnology company creating a pipeline of therapeutic antibodies against under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelope proteins, using its proprietary MPS Discovery Engine®. This platform is built on the company’s Lipoparticle and Shotgun Mutagenesis technologies and over 15 years of experience optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Integral Molecular discovers antibodies for partners in parallel with its own independent work developing antibodies for licensing. The company currently has therapeutic programs focused on pain, metabolic diseases, and viral pathogens.
Integral Molecular, Inc.
Benjamin Doranz, 215-966-6061